

Important Product Information

Ketorolac Trometamol 30 mg/ml solution for injection

FA-2026-006

March 11, 2026

Dear Sir/Madam

Baxter Healthcare Corporation, in agreement with the MHRA is issuing an Important Product Information letter for the products listed below to inform you of the important updates made to the Product Information Leaflets (PIL).

Details:

- Ketorolac Trometamol 30 mg/ml solution for injection is indicated for the short-term management of moderate to severe acute post-operative pain.
- Treatment should only be initiated in hospitals. The maximum duration of treatment is two days.
- **For Ketorolac, the PIL was updated as follows:** Tell your doctor if you recently had or you are going to have surgery of the stomach or intestinal tract before taking Ketorolac, as Ketorolac can sometimes worsen wound healing in your gut after surgery (PIL section 2). The specific batches listed in the table below do not contain this updated verbiage in the PIL.

Affected Product

Product Code	Description	GTIN	Lot Number	Expiration Date
AIN00394	Ketorolac Trometamol 30 mg/ml solution for injection	Carton GTIN Number: 55413760137341 Unit GTIN Number: 05413760137346	B5H0070A	31-Mar-2026
			B5H0224B	31-Jul-2026

Actions to be Taken by Customers

1. If you distribute this product to other facilities or to departments within your institution, please forward a copy of this communication to those locations.
2. Complete the enclosed customer reply form and return it to Baxter by scanning and e-mailing it to (uk_shs_fca@baxter.com), even if you don't have any inventory. Returning the customer reply form promptly will confirm your receipt of this notification and prevent you from receiving repeat notices.
3. If you purchased this product from a distributor, please note that the Baxter customer reply form is not applicable. If a reply form is provided by your distributor or wholesaler, please return it to the supplier according to their instructions.
4. If you are a dealer, wholesaler, distributor/reseller, or original equipment manufacturer (OEM) that distributed any affected product to other facilities, please notify your customers of this Important Product Information in accordance with your customary procedures.

Call for Reporting

Please continue to report suspected adverse drug reactions (ADRs) to the MHRA through the Yellow Card scheme [Yellow Card | Making medicines and medical devices safer](https://yellowcard.mhra.gov.uk) (<https://yellowcard.mhra.gov.uk>)

Contact Baxter Product Surveillance via the [Baxter - Product Feedback Portal](https://productfeedback.baxter.com) (<https://productfeedback.baxter.com>) to report any issue.

Further Information and Support

For general questions regarding this communication or any product issue you are experiencing, contact Baxter uk_shs_fca@baxter.com

The local Ministry of Health (MOH) has been notified of this action.

We apologize for any inconvenience this may cause you and your staff.

Sincerely,



Name: Lindsey Hilton

Title: Business Unit Head, Infusion Therapies & Technologies and Pharma
Baxter Healthcare Limited

Enclosures: Baxter Customer Reply Form